WuXi XDC Cayman Inc
2268
Clasificación en acciones
#1886
WuXi XDC Cayman Inc. operates as an investment holding company and a global... WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
Precio por acción
$8.78
Capitalización bursátil
$11.12B
Cambio (1 día)
-9.52%
Cambio (1 año)
0.57%
País
CN
Comercio WuXi XDC Cayman Inc (2268)
Categoría
Healthcare
Ratio P/B de WuXi XDC Cayman Inc (2268)
Ratio P/B al October 2026 TTM: 6.53
Según los informes financieros más recientes y el precio de las acciones de WuXi XDC Cayman Inc, el ratio P/B actual (TTM) es 6.53. Al final de 2024, el ratio P/B era 5.20.
Historial del ratio P/B de WuXi XDC Cayman Inc desde 2020 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | 6.53 | -2.87% |
| 2025 | 6.72 | 29.37% |
| 2024 | 5.20 | -10.37% |
| 2023 | 5.80 | -70.54% |
| 2022 | 19.68 | -98.47% |
| 2021 | 1.29K | 1,641.63% |
| 2020 | 73.89 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 4.5801 | -29.83% |
US
|
|
| 3.0725 | -52.93% |
US
|
|
| 31.4903 | 382.47% |
US
|
|
| 4.9326 | -24.43% |
CN
|
|
| 6.8081 | 4.31% |
US
|
